Thursday, 5 November 2026
M
Meridian Globe
Live briefing
DBS chief warns of 'choppy' equity markets after US midterms— 日经 Nikkei AsiaFrance's Tikehau, Natixis look to Asia as US data center boom raises risks— 日经 Nikkei AsiaChina's curbs on tungsten used in drill bits squeeze AI supply chain— 日经 Nikkei AsiaIndian capital doubles parking fees, asks 50% remote work to curb pollution— 日经 Nikkei AsiaNorth Korea's patient cyber operations pay off in crypto— 日经 Nikkei AsiaMalaysia's main opposition calls for greater power for states— 日经 Nikkei AsiaJapan logistics startups expand cold food networks in Malaysia, Vietnam— 日经 Nikkei AsiaFast-growing India is the next North America for Japan's Marubeni: CEO— 日经 Nikkei AsiaDBS chief warns of 'choppy' equity markets after US midterms— 日经 Nikkei AsiaFrance's Tikehau, Natixis look to Asia as US data center boom raises risks— 日经 Nikkei AsiaChina's curbs on tungsten used in drill bits squeeze AI supply chain— 日经 Nikkei AsiaIndian capital doubles parking fees, asks 50% remote work to curb pollution— 日经 Nikkei AsiaNorth Korea's patient cyber operations pay off in crypto— 日经 Nikkei AsiaMalaysia's main opposition calls for greater power for states— 日经 Nikkei AsiaJapan logistics startups expand cold food networks in Malaysia, Vietnam— 日经 Nikkei AsiaFast-growing India is the next North America for Japan's Marubeni: CEO— 日经 Nikkei Asia

[Comment] Mitapivat in the RISE UP trial: a new therapy for sickle cell disease

Source 柳叶刀 Lancet12d ago
Summary

Sickle cell disease is the most common haemoglobinopathy, affecting more than 7 million people worldwide.1 Despite substantial morbidity and mortality, access…

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
Health
Region
United Kingdom
Language
English
Item ID
health-7abf72c7

Comments 0 comments

No comments yet. Be the first.

[Comment] Mitapivat in the RISE UP trial: a new therapy for sickle cell disease · Meridian Globe